{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Grade 1 or 2 Hypertension"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 2 Hypotension"}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"description":"The number of participants who meet markedly abnormal criteria for vital signs, included diastolic and systolic blood pressure, heart rate, oral temperature, respiratory rate, and body weight.","groups":[{"description":"Ixazomib 4 mg, capsules, orally, once on Days 1, 8, and 15; lenalidomide 25 mg, capsules, orally, once on Days 1 through 21; and dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15, and 22 of a 28-day treatment cycle until progressive disease (PD) or unacceptable toxicity (up to 20 cycles)","id":"OG000","title":"Ixazomib+Lenalidomide+Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Safety population was defined as all participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"From the first dose of study drug through 30 days after the last dose of study drug (up to 577 days)","title":"Number of Participants With Clinically Significant Vital Signs Reported as Adverse Events","type":"PRIMARY","unitOfMeasure":"participants"}